Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
2015/05/31 by James Larkin, Vanna Chiarion-Sileni, Vanna Chiarion‐Sileni +37 · 8,205 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Cancer #Cancer Immunotherapy and Biomarkers #Cancer research #Dermatology #Immunotherapy #Immunotherapy and Immune Responses #Internal medicine #Ipilimumab #Medicine #Melanoma #Melanoma and MAPK Pathways #Metastatic melanoma #Nivolumab #Oncology
paper · pdf · doi:10.1056/nejmoa1504030
published in New England Journal of Medicine 373(1), 23-34 (Massachusetts Medical Society)
openalex publication_date 2015/05/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06
Abstract
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. METHODS: We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here. RESULTS: The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group. CONCLUSIONS: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
Cited by
- The Autophagy Receptor Adaptor p62 is Up‐regulated by UVA Radiation in Melanocytes and in Melanoma Cells
- The diversity of CD8+ T cell dysfunction in cancer and viral infection
- CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
- Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
- Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
- Clinical protein science in translational medicine targeting malignant melanoma
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Novel patterns of response under immunotherapy
- PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines
- Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
- The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
- Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects
- Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors
- Immune Checkpoint Inhibitors: Basics and Challenges
- The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
- Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases
- Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy
- Immune checkpoint inhibitors and acute kidney injury
- Direct Detection and Quantification of Neoantigens
- A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- Phosphatidylserine: A cancer cell targeting biomarker
- Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis
- Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
- Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
- Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo
- Melanoma: Pathogenesis and Targeted Therapy
- Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor‐induced colitis
- Impaired B‐cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
- Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
- HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
- The gut microbiota influences anticancer immunosurveillance and general health
- Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
- Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy
- First line Immunotherapy for Non-Small Cell Lung Cancer
- JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy
- De-novo and acquired resistance to immune checkpoint targeting
- Lung cancer
- Human αβ and γδ T Cells in Skin Immunity and Disease
- Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence
- Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
- Independent drug action and its statistical implications for development of combination therapies
- 「石の骨」, 著者 松本清張, 新潮文庫(読書のすすめ)
- Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease
- PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment
- Surgical Considerations and Systemic Therapy of Melanoma
- Advances in immunotherapy for melanoma
- Toxicity management of immunotherapy for patients with metastatic melanoma
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. [europepmc]
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. [europepmc]
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. [europepmc]
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. [europepmc]
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. [europepmc]
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. [europepmc]
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. [europepmc]
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade. [europepmc]
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy. [europepmc]
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [europepmc]
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. [europepmc]
- Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. [europepmc]
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. [europepmc]
- Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. [europepmc]
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [europepmc]
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. [europepmc]
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. [europepmc]
- Regulation and Function of the PD-L1 Checkpoint. [europepmc]
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. [europepmc]
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. [europepmc]
- Immune checkpoint inhibitors: recent progress and potential biomarkers. [europepmc]
- The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. [europepmc]
- Immunotherapy in colorectal cancer: rationale, challenges and potential. [europepmc]
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. [europepmc]
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. [europepmc]
Related